These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26826182)

  • 1. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
    Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
    Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
    Kobayashi-Watanabe N; Sato A; Watanabe T; Abe T; Nakashima C; Sueoka E; Kimura S; Sueoka-Aragane N
    Lung Cancer; 2017 Aug; 110():35-41. PubMed ID: 28676216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
    Lee MS; Jung EA; An SB; Kim YJ; Oh DY; Song JY; Um SW; Han J; Choi YL
    Cancer Res Treat; 2017 Oct; 49(4):1065-1076. PubMed ID: 28161936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
    Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M
    Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.
    Miao L; Wang Y; Zhu S; Shi M; Li Y; Ding J; Yang J; Ye Q; Cai H; Zhang D; Liu H; Song Y
    BMC Cancer; 2014 May; 14():369. PubMed ID: 24885564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
    Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB
    Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J
    Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
    Iwai LK; Payne LS; Luczynski MT; Chang F; Xu H; Clinton RW; Paul A; Esposito EA; Gridley S; Leitinger B; Naegle KM; Huang PH
    Biochem J; 2013 Sep; 454(3):501-13. PubMed ID: 23822953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.
    Huo Z; Wu H; Li S; Liang Z
    Diagn Pathol; 2015 Sep; 10():161. PubMed ID: 26373952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing.
    Ricordel C; Lespagnol A; Llamas-Gutierrez F; de Tayrac M; Kerjouan M; Fievet A; Hamdi-Rozé H; Aliouat A; Desrues B; Mosser J; Léna H
    Clin Lung Cancer; 2018 Mar; 19(2):163-169.e4. PubMed ID: 29129434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
    Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
    Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
    Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
    Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
    Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
    Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
    Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.